indication

Marijuana Abuse

Competitive landscape

as of 2026-07-01
Competitive set
3
2 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
30 events
2020
2024
2028
2032
2036
2040
2044
2048
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugActive Not Recruiting
Risperidone
US-approved 1993 · RISPERDAL
Phase 44 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Clozapine
US-approved 1989 · Clozaril
Phase 43 trials
OwnerShanghai Mental Health Center
Protection2028
drugActive Not Recruiting
Cannabidiol
Pipeline · Phase 2
Phase 25 trials
OwnerCentral Institute of Mental Health, Mannheim
Protection—

Market size

prevalence as a range, not a number